Exclusive Distribution of an orphan drug

The company begun with the delivery of targeted immunotherapy for a rare disease and obtained exclusive distribution rights for this innovative and original medicine used to treat high-risk neuroblastoma, a rare disease – rare form of cancer arising from neural crest cells, the most frequently occurring solid tumour in infants under one year old. This innovative medicine, which is becoming the standard of care in the treatment of high-risk neuroblastoma, is now available in Serbia, marking a vital step forward in treating young children diagnosed with this aggressive type of cancer. The company has become a member of the group of wholesalers within the Serbian Chamber of Commerce, which holds full membership status in GIRP – the European Healthcare Distribution Association.